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ambulatory setting [2] (cost base year 2005). As only costs were considered, no dis-
counting was applied. RESULTS: In the ﬁrst year after initiating a BOT, costs per 
patient are slightly higher (a3.25) in GLA- than NPH-based regimens. From year two 
GLA regimens show an increasing cost advantage compared to NPH up to a1,217 
per patient after 10 years. As all patients have changed to ICT at year 10, a longer 
time horizon would not change the ﬁndings. Calculated for an estimated cohort of 
44,366 German T2D covered by the SHI and starting a BOT with GLA (50%) or 
NPH (50%), the total costs over 10 years are a169.7 vs. a223.7 million, respectively. 
CONCLUSIONS: Due to a longer persistence to a basal supported oral therapy in 
T2D, long-term costs of GLA are lower compared to NPH. Therefore, initiating an 
insulin therapy using BOT with GLA leads to potential cost savings of a54 million 
per 10 years for the German SHI. References: [1] Diabetologie und Stoffwechsel 
2009;4:1–6 [2] J Med Econ 2008;11:695–712.
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OBJECTIVES: To compare resource utilization and costs of type-2 diabetic (T2D) 
patients treated with either insulin glargine (GLA) or insulindetemir (DET) in a basal-
bolus regimen. METHODS: LIVE-COM* was a non-interventional study in 138 
primary care centres in Germany (representative sample). 1731 T2D patients with 
statutory health insurance (SHI) status were enrolled when either treated with GLA 
(n  1150) or DET (n  581) in a basal-bolus regimen for at least 6 months prior to 
documentation. Total direct diabetes treatment costs (DTC) derived from antidiabetic 
medications (insulins, oral drugs) and consumables (test strips, lancets, needles) were 
assessed retrospectively over 6 months. RESULTS: Respective patient characteristics 
(mean) for GLA (53% male) and DET (49% male): age: 66/65 years, BMI: 
31.3/32.7 kg/m², HbA1c: 7.5/7.7%, fasting blood glucose: 140/148 mg/dl, onset of 
diabetes 10 yrs ago: 60/59%, start of insulin therapy 5 yrs ago: 62/64%, number 
of diabetic complications (3.0/2.9). Resource use: Compared to DET, GLA patients 
had on average fewer basal insulin injections per day (1.1 vs. 1.3) and required sig-
niﬁcantly less test strips (3.2 vs. 3.6). Mean daily total insulin dose (basal/bolus) was 
signiﬁcantly lower in GLA (27.7/40.3 U) compared to DET (32.1/47.1 U). Reported 
hypoglycemia, hospitalization rates and frequency of physician contacts did not differ 
between groups. Adjusted mean DTC per patient and 6 months were a932 (GLA) vs. 
a1061 (DET); p  0.001. Adjusted mean single costs (GLA vs. DET) were: basal insulin 
a223/246 (p  0.001), bolus insulin a241/289 (p  0.001), oral drugs a37/36 (ns), test 
strips a347/393 (p  0.001), needles a68/80 (p  0.001), lancets a14/16 (ns). CON-
CLUSIONS: Insulin glargine based basal-bolus regimens resulted in annual cost 
savings of a256 per patient compared to DET regimens from the SHI perspective in 
Germany. GLA patients showed better glycemic control under routine care conditions. 
*Long acting Insulin glargine Versus Insulin detemir cost Evaluation COMparison.
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OBJECTIVES: Cost comparison of insulin glargine (IG) versus insulin detemir (ID) in 
a basal-bolus regime with mealtime insulin aspart in type 2 diabetes patients (T2D) 
in Germany. METHODS: Clinical data were taken from a randomised controlled trial 
[1]. IG was administered once daily, ID once or twice daily. Mean daily insulin doses 
(basal :bolus) were 0.59 and 0.32 U/kg for IG and 0.82 and 0.36 U/kg for ID. Gly-                 
caemic control, weight gain, adverse events and risk of hypoglycaemia were similar 
in both groups after 1 year (non inferiority trial) so a cost minimisation analysis was 
undertaken. Costs were calculated from the perspective of the statutory health insur-
ance (SHI) using ofﬁcial 2008 prices. It was assumed that a new needle, lancet and 
test strip were used at the time of each injection. RESULTS: The annual single costs 
per patient for needles were a393 for IG and a449 for ID. The costs of blood glucose 
test strips and lancets were a1125 for IG and a1286 for ID. The overall costs of 
basal-bolus insulin were a1,607 for IG and a2144 for ID. The total annual costs per 
patient was a3126 for IG compared with a3879 for ID, translating into a 19% annual 
cost saving of a753/patient in favour of IG. Sensitivity analyses conﬁrmed the robust-
ness of the results. CONCLUSIONS: IG and ID basal-bolus regimes have comparative 
safety and efﬁcacy outcomes, based on [1], IG however may represent a signiﬁcantly 
more cost saving option for T2D patients in Germany requiring basal-bolus insulin 
analogue therapy with potential cost savings of a753a (19%) compared to ID. REFER-
ENCE: [1] Hollander P et al.. A 52-week, multinational, open-label, parallel-group, 
noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in 
a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. 
Clinical Therapeutics 2008;30:1976–87. Study supported by sanoﬁ-aventis.
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OBJECTIVES: Different insulin regimes may have different efﬁcacy that can be bal-
anced by higher dosing, which means higher costs. Payers are considered to choose 
the more cost effective therapies, and pay less for the same efﬁcacy results. Aim of 
our study was to determine the cost born on payers reimbursing basal analoge insu-
lines. METHODS: We used two studies were designed to achieve the same clinical 
beneﬁt, such as non-inferiority studies. This way the effectiveness will be the same and 
we could focus on costs only. Dose differences were multiplied with actual Hungarian 
costs of insulins RESULTS: We used an article by Rosenstock compared basal ana-
logue insulins in BOT indication and another article by Hollander done on ICT indica-
tion. In the Rosenstock study patients required an average 31 unit higher daily insulin 
dose on detemir than on glargin, to achieve the same clinical effectiveness as there 
was no signiﬁcant difference in terms of HbA1c levels. Using Hugarian drug costs, 
this higher dose with detemir related to an extra cost of HUF 111,887 per year. The 
case was the same with the Hollander study where detemir patients required on 
average 22.5 unit higher daily dose of basal insulins and 4.3 unit more rapid insulin 
on daily average. In the Hungarian health care system this gives an extra cost of HUF 
94,182 on yearly average. CONCLUSIONS: In clinical trials detemir patients requires 
signiﬁcantly more insulin than glargin patients to achieve the same clinical beneﬁt, 
which would result in a signiﬁcantly higher cost in the Hungarian health care 
system.
PDB38
COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE 
COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL 
THERAPY (BOT) IN GERMANY
Neilson A1, Pscherer S2, Dippel FW3, Dietrich ES1
1HealthEcon AG, Basel, Switzerland, 2Klinikum Traunstein, Traunstein, Germany, 3Sanoﬁ-
Aventis, Berlin, Germany
OBJECTIVES: Cost comparison of basal insulin analogues detemir (ID) and glargine 
(IG) in combination with oral antidiabetic drugs (basal supported oral therapy; BOT) 
for type-2 diabetes patients in Germany. METHODS: Clinical data were taken from 
a randomised controlled clinical trial (RCT) [1]. IG was administered once daily, ID 
was administered once (45%) or twice daily (55%). After 52 weeks mean daily ID 
dose was 77% higher (0.78 U/kg) than IG dose (0.44 U/kg). Glycemic control, weight 
gain, adverse events and risk of hypoglycemia were comparable after one year (non 
inferiority trial) so a cost minimisation analysis was undertaken. It was assumed that 
a new needle, lancet, and test strip was used at the time of each injection. Annual 
direct treatment costs were estimated from the perspective of the German statutory 
health insurance (SHI). Simulated resources included medication and consumable 
items. Initial and ﬁnal insulin doses and proportion of patients with once/twice daily 
insulin injection were taken from the RCT. Unit costs were taken from ofﬁcial German 
sources. Deterministic- (DTA) and probabilistic sensitivity analyses (PSA) on resource 
use and unit costs were performed. RESULTS: Average annual treatment costs per 
patient (base case) were a941 for IG and a1406 for ID (annual cost saving a464). 
Single costs of consumable items amounted at a380 (IG) and a588 (ID) respectively. 
Sensitivity analyses conﬁrmed the ﬁndings in favour of glargine. PSA results found 
cost savings could be at least a500 with a probability of ^59%. CONCLUSIONS: 
The current model estimated that IG was associated with lower annual treatment costs 
of a464 (33%) compared to the use of IG. REFERENCE: [1] Rosenstock J et al. A 
randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin 
glargine when administered as add-on to glucose-lowering drugs in insulin-naive 
people with type-2 diabetes. Diabetologia 2008;51:408–16.
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OBJECTIVES: To perform a comparative analysis of the costs linked to the treatment 
with Insulin Glargine (IG) or Insulin Detemir (ID) in type 1 diabetes mellitus patients 
from the Mexican private market perspective. METHODS: Clinical data related to 
each treatment derives from a study performed by Pieber and cols. (2008): a 26-week 
open-label, parallel trial, which compares efﬁcacy and safety of IG and ID both in 
combination with insulin aspart. Primary objective in efﬁcacy was HbA1c and 
hypoglycaemias tolerability. HbA1c control is equivalent in the two regimens, while 
the overall risk of hypoglycaemias had no differences in conﬁrmed hypoglycaemias. 
Patients treated with IG required higher bolus dose, but lower basal and total dose of 
insulin. The cost of each treatment regimen was calculated using the unit cost of             
insulin, needles, and blood glucose tests (BGT). Costs calculations referred to year           
2009 and were derived from published tariffs. Sensitivity analysis was performed using 
a Monte Carlo simulation. RESULTS: Overall, patients treated with ID required 
13.5% more total insulin, and 20% more needles and BGT than IG patients. Manage-
ment with IG has lower total costs than ID, which allows savings of a203 per patient 
in the 26 weeks-period. Savings with IG were related to the costs of total insulin, and 
the lower injections required of basal insulin. Sensitivity analysis showed savings from 
a58 to a651 between the percentiles 25 and 95. CONCLUSIONS: For patients with 
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DM1, treatment with IG is an efﬁcacious and cost-saving option compared with ID, 
because Insulin Glargine is associated with a comparable efﬁcacy and lower total costs 
versus ID allowing savings for up to 17.3% per patient-year.
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OBJECTIVES: To evaluate cost-utility of biphasic insulin aspart (BIAsp) compared 
with premixed human insulin (Premix) in type-2 diabetes mellitus. METHODS: A 
cost-utility analysis based on The CORE Diabetes Model was conducted, resulting in 
estimation of total direct costs incurred by the National Health Fund and patients, 
life years gained (LYG) and quality-adjusted life years (QALY). The CORE Diabetes 
Model is a complex tool allowing for evaluation of long term health and economic 
outcomes of different treatment options in diabetes mellitus. It is designed as a Markov 
model using Monte Carlo simulations and is based on a series of interconnected sub-
models representing diabetes complications. Cohort baseline characteristics and base-
line distribution between states in the model were derived from published literature. 
Treatments were deﬁned in the means of a change in HbA1c level and hypoglycaemia 
rates calculated on the base of systematic review of RCTs. Default settings were used 
regarding to transition probabilities and utilities of health states. Costs from the 
NHFpatient perspective were calculated. Time horizon in the model was set to 30 
years or until death. In order to estimate the probability of BIAsp being cost effective 
in Polish setting (threshold about 91,000 PLN) bootstrap simulations were performed. 
RESULTS: Both treatments were comparable in terms of LYG (7.47 for BIAsp and 
7.46 for Premix), but BIAsp yielded higher QALY (5.06 vs. 4.95 for BHI). Costs gener-
ated by BIAsp were 30,079 PLN and by premixed insulin 24,970 PLN. Incremental 
cost per QALY for BIAsp compared with Premixed was 49,425 PLN. Probability of 
BIAsp cost effectiveness over Premixed was 63% for QALY and 41% for LYG. 
CONCLUSIONS: Biphasic insulin aspart improves quality of life what translates to 
higher QALY. Despite higher costs associated with treatment, biphasic insulin aspart 
seems to be cost-effective in Polish setting.
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OBJECTIVES: To evaluate cost-utility of insulin glargine (IGlar) in combination 
therapy with oral antidiabetic drugs (OAD) compared with premix insulin (IMix) 
added to OAD and IMix alone in patients with type 2 diabetes. METHODS: A micro-
simulation DES model was used to estimate utilities and costs. Costs were calculated 
from the National Health Fund (NHF) perspective and form NHF plus patient per-
spective. Simulation was executed in one year cycles and terminated at the time of the 
patient’s death. Transition probabilities between health states were calculated based 
on a systematic review of RCTs and supplemented with published literature if neces-
sary. Health states utilities were taken from published literature. Probabilistic sensitiv-
ity analysis was performed to estimate the probability that IGlar with OAD is cost 
effective in Polish settings (threshold about 91,000 PLN). RESULTS: From NHF per-
spective IGlar added to OADs compared with IMix added to OADs was dominant 
therapy e.g less costly (cost difference PLN2,496) and more effective (QALY difference 
0.19) and from NHF plus patient perspective incremental costs were PLN34,662 per 
QALY gained. When compared with insulin mixtures alone, IGlar added to OADs 
was dominant therapy from NHF perspective e.g less costly (cost difference 
PLN1,1105) and more effective (QALY difference 0.13) and from NHF plus patient 
perspective incremental costs were PLN19,800 per QALY gained. From NHF perspec-
tive the probability of IGlarOAD cost effectiveness over IMixOAD was 96.9%,and 
IGlarOAD over IMix alone was 95.7%. From NHF plus patient perspective the 
probability of IGlar cost effectiveness over IMix with OAD was 86.7% and IGlarOAD 
over IMix alone was 82.8%. CONCLUSIONS: According to this analysis performed 
in Poland, Insulin glargine, when added to OADs, seems to be more cost effective then 
insulin mixture, both in combination with OADs and alone.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: Type 2 diabetes is a difﬁcult disease to manage and treatment is often 
suboptimal for many patients, in particular with insulin therapy. Preﬁlled insulin pens 
provide patients with an easier-to-manage regimen that might lead to improved adher-
ence compared to vial/syringe use. This study analyzed the impact of switching from 
analog insulin in vials to the preﬁlled pen, FlexPen®. METHODS: Real world data 
from a large commercial health plan in the US were investigated and insulin daily 
average consumption (DACON), hypoglycemic events and health care costs were 
analyzed before and after switch to FlexPen®. To control for the general change in 
insulin consumption the FlexPen® cohort was compared to a matched cohort that 
continued analog insulin in vials. RESULTS: A total of 532 patients switched to 
FlexPen® were matched to a cohort continuing on an analog insulin (n  532) admin-
istered by vial/syringe. Insulin DACON increased in both cohorts by 6–10% from the 
12-month pre-period to the 12-month post-period. However, DACON increased 
approximately 2 units more among patients switching to FlexPen® than the vial/
syringe cohort (p  0.0299). In addition, hypoglycemic event rates decreased in the 
FlexPen® cohort from 6.39% in the pre-period to 4.89% in the post-period while 
hypoglycemic events increased in the vial/syringe cohort from 4.89% to 5.83%. 
Despite higher acquisition costs of FlexPen® vs. vials there were no differences in 
pharmaceutical costs (5,414 vs. 4,790; p  0.08) or total costs (13,214 vs. 13,211; p 
 0.95) in the follow-up period. CONCLUSIONS: Patients switched to FlexPen® 
administration experienced an increase in DACON compared to the analog vial 
cohort, which is likely to be associated with improved adherence. Despite increase in 
DACON with FlexPen®, total health care and pharmaceutical costs were similar 
between groups in the follow-up period. Hypoglycemic events decreased in the 
FlexPen® cohort while they increased in the analog vial cohort.
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OBJECTIVES: Few studies have examined the association between medication adher-
ence and age in low income elderly type 2 diabetes patients. The study objective was 
to determine the age associated medication adherence among low-income type-2 dia-
betes patients enrolled in Medicaid. METHODS: This was a retrospective cohort 
study, which compared medication adherence among different age groups of Medicaid 
insured patients with type-2 diabetes newly starting oral antidiabetic medication. The 
study compared the differences in medication adherence among 681 patients aged 
18–44 years, 2327 patients aged 45–64 years and 161 patients aged 65 years newly 
starting antidiabetic medication between July 2001 and June 2002. Medication adher-
ence was measured as medication possession ratio using prescription reﬁll patterns. 
Multiple regression analyses were used to determine the difference in adherence rates 
after adjusting for different covariates. RESULTS: Medication adherence rate was 
signiﬁcantly higher for age group 65 years [0.59 0.31), (p  0.05)] as compared to 
age groups 18–44 years [0.56 (0.31), (p  0.05)] and 44–64 years [0.22 (0.17), (p  
0.05)] respectively. Multiple regression analyses showed that compared to age group 
18–44 years, age groups 65 and 44–64 years had signiﬁcantly higher adherence rate 
by 13.4% and 12.5% respectively. Metformin users were associated with a 34.5% 
decrease in adherence rate as compared to the sulfonylurea users (p  0.05). CON-
CLUSIONS: Better oral antidiabetic medication adherence was associated with 
increased age. Future research should investigate patient-related factors affecting medi-
cation adherence with an emphasis on the development of efﬁcient medication man-
agement therapies which may in turn, reduce health care costs and disease burden in 
low-income elderly diabetic patients.
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OBJECTIVES: To examine the relationship between Hemoglobin A1c (HbA1c) values 
and medication adherence over time in diabetic patients participating in a pharmacist-
conducted Medication Therapy Management program (MTMP). METHODS: This 
study used a prospective, intention-to-treat, pre-post longitudinal design assessing the 
impact of a pharmacist-conducted employer sponsored MTMP on clinical and human-
istic outcomes of employees, their spouses and covered dependents with Type 2 dia-
betes. Enrollment began in January 2008. As an incentive to participate, patients 
received a 3 month supply of medications at the cost of one copay. Pharmacist inter-
ventions included medication therapy reviews, discussing details about patients’ 
disease state and the importance of medication adherence, and informing patients 
about appropriate lifestyle modiﬁcations. HbA1c was measured using the Cholestech 
LDX at the pharmacy every three months and adherence was measured at baseline, 
3 months, and nine months. Patient reported adherence was measured using the 
Morisky scale. Currently, most patients have completed six months in the program 
therefore analysis focused on comparing baseline and the three month time point. A 
Wilcoxon signed-rank test was used to determine changes in HbA1c values over time 
and a Spearman correlation was used to examine any relationship. RESULTS: Patients 
who began the program with uncontrolled HbA1c values experienced a signiﬁcant 
decrease of 0.79% in HbA1c values from baseline to 3 months. Adherence levels 
improved signiﬁcantly from baseline to 3 months (p  0.05). There was a signiﬁcant 
inverse relationship between A1c levels and medication adherence at 3 months (Spear-
man’s R  0.264, A  0.05, N  70). Final results will be presented at the conference. 
CONCLUSIONS: As adherence to medications increased there was a decrease in 
HbA1c values. Patients with improved adherence were able to maintain better 
